Open AccessRivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?
Author(s) -
Flávia Caló Aquino Xavier,
Paulo M. Hoff,
Maria Ignez Braghiroli,
Ana Carolina Carvalho Rocha Paterlini,
Karla Teixeira Souza,
Luiza Dib Batista Bugiato Faria,
Fernando Sérgio Blumm Ferreira,
Karime Kalil Machado,
Gustavo dos Santos Fernandes
Publication year - 2017
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2015.002527
Subject(s) - rivaroxaban , medicine , low molecular weight heparin , thrombosis , vitamin k antagonist , pulmonary embolism , cancer , venous thrombosis , retrospective cohort study , anticoagulant , surgery , gastroenterology , warfarin , atrial fibrillation
Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold-standard treatment, but the costs involved limit its use, especially in developing countries. Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE treatment.